Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enobosarm - Veru Healthcare

Next Previous
Drug Profile

Enobosarm - Veru Healthcare

Alternative Names: GTx-024; MK-2866; Ostarine; S-22; VERU-024

Latest Information Update: 10 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University Research Foundation; University of Tennessee Research Foundation
  • Developer Oncternal Therapeutics, Inc.; Veru Healthcare
  • Class Antineoplastics; Nitriles; Obesity therapies; Osteoporosis therapies; Small molecules; Urologics
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Obesity
  • Preclinical Unspecified
  • No development reported Postmenopausal osteoporosis
  • Discontinued Cachexia; Duchenne muscular dystrophy; Muscular atrophy; Urinary-Stress-Incontinence

Most Recent Events

  • 04 Aug 2026 Veru Healthcare files for patent protection with for novel, oral, modified-release enobosarm formulation
  • 04 Aug 2026 Veru Healthcare receives patent allowance for compositions comprising selective androgen receptor modulator compounds in combination with semaglutide and uses thereof for quality weight loss in the USA
  • 09 Mar 2026 Phase-II clinical trials in Obesity (Combination therapy, In the elderly, Treatment-experienced) in USA (PO) (NCT07446998)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top